<ul><li>PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has raised $34M in Series D funding.</li><li>The funding will accelerate the development of PrognomiQ's early detection test for lung cancer, which leverages a multi-omics approach.</li><li>PrognomiQ has demonstrated promising results, including a recent study showing 89% sensitivity and specificity in detecting lung cancer.</li><li>With the new funding, PrognomiQ aims to advance the development and commercialization of its lung cancer detection test.</li></ul>

PrognomiQ Raises $34M to Advance Multi-Omics Early Detection Test for Lung Cancer

Discover more